Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1258 • ACR Convergence 2021
Measurement of Specific Organ Domains in Lupus Randomised Controlled Trials
Kathryn Connelly¹, Jeevan Vettivel², Vera Golder², Rangi Kandane-Rathnayake² and Eric Morand³, ¹Monash University, Camberwell, Australia, ²Monash University, Clayton, Australia, ³Monash University, Melbourne, Australia
Background/Purpose: Randomised controlled trials (RCTs) in SLE typically adopt composite responder definitions as primary efficacy endpoints, however outcomes within individual organ domains are also important…
Abstract Number: 1274 • ACR Convergence 2021
Severe Flares Are Associated with a Poorer Health-Related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE) Patients
Manuel Ugarte-Gil¹, Rocio Gamboa-Cardenas², Cristina Reategui-Sokolova³, Victor Pimentel-Quiroz¹, Mariela Medina⁴, Claudia Elera-Fitzcarrald², Francisco Zevallos⁴, Cesar Pastor-Asurza⁵, Federico Zazzetti⁶, Chetan Karyekar⁷, Risto Perich-Campos⁵ and Graciela Alarcn⁸, ¹Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ²Universidad Cientifica del Sur/Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ³Hospital Guillermo Almenara Irigoyen, Lima, Peru, ⁴Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁵Universidad Nacional Mayor de San Marcos/Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁶Medical Affairs, Jan-Cil Argentina, Buenos Aires, Argentina, ⁷Janssen R&D, Spring House, PA, ⁸University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Flares in SLE patients, regardless of their severity, have been associated with damage accrual. However, their impact on HRQoL has not been fully evaluated.…
Abstract Number: 1290 • ACR Convergence 2021
Validation of a Novel Lupus Multivariable Outcome Score as an Outcome Measure for Systemtic Lupus Erythematosus Trials
Michal Abrahamowicz¹ and Peter Lipsky², ¹McGill University, Montréal, QC, Canada, ²AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Development of effective new Systemic Lupus Erythematosus (SLE) treatments requires a validated responder index responsive to clinically meaningful change and relevant to clinical practice.…
Abstract Number: 1422 • ACR Convergence 2021
Urinary CD163 Predicts Proliferative Lupus Nephritis in SLE Patients with Proteinuria: A Practical Liquid Biopsy Approach
Andrea Fava¹, Jessica Li¹, Daniel Goldman², Jose Monroy-Trujillo¹, Mohamed G. Atta¹, Derek Fine¹, Jill Buyon³, Joel Guthridge⁴, Judith James⁴, Michelle Petri² and Accelerating Medicines Partership (AMP) RA/SLE Network⁵, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³NYU School of Medicine, New York, NY, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Brigham and Women's Hospital, Everett, MA
Background/Purpose: Diagnosis of lupus nephritis (LN) relies on a kidney biopsy obtained in SLE with proteinuria. Delayed access to kidney biopsies may delay diagnosis and…
Abstract Number: 1481 • ACR Convergence 2021
Malondialdehyde-acetaldehyde Antibodies Occur in Systemic Lupus Erythematosus and Associate Specifically with Neuropsychiatric Involvement
Rory Monahan, Michelle van Beukel, Nicole Borggreven, Margreet Kloppenburg, Tom WJ Huizinga, Gerda Steup-Beekman and Leendert Trouw, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogenous autoimmune disease characterized by a global loss of self-tolerance. Although autoantibodies are an important hallmark of SLE,…
Abstract Number: 1501 • ACR Convergence 2021
Molecular Modelling Predicts Inhibition of Functional Effects of Anti-thrombin III on Factor Xa Mediated Complement Activation by Anti- Factor Xa IgG in SLE and APS
Thomas McDonnell¹, Raj Amarnani², Valentina Spiteri², Carina Spicer³, Charis Pericleous⁴, Bahar Artim-Esen⁵, Ian Mackie¹, Marina Botto⁴, Anisur Rahman¹ and Ian Giles¹, ¹University College London, London, United Kingdom, ²University College London, London, ³Merck, Philadelphia, PA, ⁴Imperial College London, London, United Kingdom, ⁵Istanbul University School of Medicine, İstanbul, Turkey
Background/Purpose: The significance of antibodies directed against activated Factor (FXa) and thrombin (Thr) found in ~40% of patients with Systemic Lupus Erythematosus (SLE) and/or Antiphospholipid…
Abstract Number: 1658 • ACR Convergence 2021
Risk of Other Autoimmune Conditions Among Relatives of Patients with Rheumatoid Arthritis
Katherine Liao¹, Thany Seyok¹ and Lisa Cannon-Albright², ¹Brigham and Women's Hospital, Boston, MA, ²University of Utah School of Medicine, Salt Lake City, UT
Background/Purpose: Autoimmune conditions appear to cluster in families, as may be expected by shared genetic risk factors in conditions such as rheumatoid arthritis (RA), autoimmune…
Abstract Number: 1742 • ACR Convergence 2021
Efficacy of Anifrolumab in Serological Subgroups of Patients with SLE Participating in 2 Phase 3 Trials
Ian N. Bruce¹, Ronald Van Vollenhoven², Yoshiya Tanaka³, Eric Morand⁴, Richard Furie⁵, Konstantina Psachoulia⁶, Emmanuelle Maho⁷, Catharina Lindholm⁸, Christi Kleoudis⁹ and Raj Tummala⁶, ¹University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴Monash University, Melbourne, Australia, ⁵Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, ⁶BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁷BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ⁸BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁹BioPharmaceuticals R&D, AstraZeneca, Durham, NC
Background/Purpose: In the TULIP-2 and TULIP-1 trials of patients with SLE, the type I IFN receptor mAb anifrolumab resulted in higher BILAG–based Composite Lupus Assessment…
Abstract Number: 1760 • ACR Convergence 2021
Long-term Opioid Use Among Patients with Systemic Lupus Erythematosus
Jesse Dabit¹, Maria Valenzuela-Almada², Mehmet Hocaoglu³, Sebastian Vallejo-Ramos¹, Shirley-Ann Osei-Onomah¹, Sara Achenbach¹, Cynthia Crowson⁴ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Division of Rheumatology, Mayo Clinic, Rochester, MN, ³University of Maryland Medical Center, Midtown Campus, Baltimore, MD, ⁴Mayo Clinic, Eyota, MN
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic condition that can be associated with both acute and chronic musculoskeletal pain as well as fibromyalgia. Opioids…
Abstract Number: 1931 • ACR Convergence 2021
The Burden of Thirty-day Readmission and Independent Predictors of Readmission in Patients with Systemic Lupus Erythematosus: A Nationwide Analysis
Ashu Acharya¹, Saffa Iftikhar¹, Yasmin Khader¹, Sachit Sharma¹, Joan N Gekonde¹, Rawish Fatima¹, Cameron J Burmeister¹ and Nezam Altorok², ¹University of Toledo Medical Center, Toledo, OH, ²University of Toledo, Toledo, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic immune-mediated disease with 20-25% patients needing hospital admission annually. Early readmissions add to the clinical and economic…
Abstract Number: L10 • ACR Convergence 2020
Targeting Plasmacytoid Dendritic Cells Improves Cutaneous Lupus Erythematosus Skin Lesions and Reduces Type I Interferon Levels: Results of a Phase 1 Study of VIB7734
Victoria Werth¹, Jodi Karnell², William Rees², Nanette Mittereder³, Li Yan², Yanping Wu³, Jorn Drappa², Gabor Illei² and John Ratchford², ¹University of Pennsylvania, Philadelphia, PA, ²Viela Bio, Gaithersburg, MD, ³Viela Bio, Gaithersburg
Background/Purpose: Plasmacytoid dendritic cells (pDCs) secrete large amounts of type I interferon (IFN) and other cytokines upon activation. pDCs migrate to sites of active disease…
Abstract Number: 0244 • ACR Convergence 2020
What Are the Early versus Late Predictors for Systemic Lupus Erythematosus (SLE) Diagnosis?
Yiting Wang¹, Kirsten Lum², Karen Costenbader³, Grace Wang⁴, Jennifer Lofland⁵, Dominik Naessens⁶, Yihan Zhao⁷, Kourtney Davis⁸ and Chetan Karyekar⁹, ¹Janssen Research & Development, LLC, Newark, DE, ²Janssen Pharm Technology - Data Sciences and Data Management, Horsham, PA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Janssen Pharmaceuticals, Horsham, ⁵Janssen Global Market Access, horsham, PA, ⁶Jassen Global Market Access, Beerse, Belgium, ⁷Janssen Pharm Technology - Data Sciences and Data Management, Horsham, ⁸Janssen R&D, LLC, Titusville, NJ, ⁹Janssen Global Services, LLC, Horsham, PA
Background/Purpose: SLE is clinically heterogenous and its diagnosis is often difficult or delayed. The length of time from symptom onset or from when patients seek…
Abstract Number: 0260 • ACR Convergence 2020
Does Higher Quality of Care in SLE Improve Quality of Life?
Shilpa Arora¹, Patricia Katz², Jinoos Yazdany³, Joel Block¹, Edward Yelin⁴ and Meenakshi Jolly⁵, ¹Rush University Medical Center, Chicago, IL, ²University of California, San Francisco, Novato, CA, ³University of California, San Francisco, San Francisco, CA, ⁴UCSF, San Francisco, CA, ⁵Rush University, Chicago, IL
Background/Purpose: Disease activity, damage and quality of life (QOL) are core outcomes in Systemic lupus erythematosus (SLE). ER visits and hospital admissions (non-routine health care…
Abstract Number: 0277 • ACR Convergence 2020
Incidence and Time to Classification of Systemic Lupus Erythematosus by Three Different Classification Criteria
Ali Duarte-Garcia¹, Mehmet Hocaoglu², Shirley-Ann Osei-Onomah³, Jesse Dabit¹, Rachel Giblon¹ and Cynthia Crowson⁴, ¹Mayo Clinic, Rochester, MN, ²University of Maryland Medical Center Midtown Campus, Baltimore, MD, ³Mayo Clinic, Rochester, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Classification criteria are standardized definitions required to identify well defined cohorts of patients for research. In practice they are also used as a framework…
Abstract Number: 0295 • ACR Convergence 2020
CCL3L3–null Status May Predispose to Systemic Lupus Erythematosus and Non-scarring Alopecia
Eunyoung Lee¹, Young-Ho Kim², Hye Won Sim², Eun-Kyung Kang², Yoon-Ho Won², Esther Park², Yeong-Wook Song³ and Kyeong-Man Hong², ¹Seoul National University Hospital, Seoul, Republic of Korea, ²National Cancer Center, Ilsan, Kyonggi-do, Republic of Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Seoul, Korea, Republic of Korea
Background/Purpose: The correlation between the copy number variation of CCL3L1 and susceptibility to systemic lupus erythematosus (SLE), rheumatoid arthritis, Kawasaki disease, and HIV infection has…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].